Drugs@FDA: FDA Approved Drug Products

Home | Previous Page

New Drug Application (NDA): 022542
Company: FOREST LABS INC

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
VIOKACE PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) 39,150USP UNITS;10,440USP UNITS;39,150USP UNITS TABLET;ORAL Prescription None Yes No
VIOKACE PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) 78,300USP UNITS;20,880USP UNITS;78,300USP UNITS TABLET;ORAL Prescription None Yes Yes

Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
03/01/2012 ORIG-1 Approval Type 7 - Drug Already Marketed without Approved NDA STANDARD Label (PDF)
Letter (PDF)
Review
Summary Review (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022542s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/022542s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022542_viokace_toc.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/022542Orig1s000SumR.pdf
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
07/29/2014 SUPPL-2 Manufacturing (CMC)

Label is not available on this site.
01/06/2014 SUPPL-1 Manufacturing (CMC)

Label is not available on this site.

Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert		 Note Url
03/01/2012 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022542s000lbl.pdf

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English